Press Release

CARDEA-Plus is designed to evaluate dosing, safety and efficacy of Auxora in combination with both tocilizumab and corticosteroids LA JOLLA, Calif., January 20, 2022 – CalciMedica Inc. (CalciMedica or the Company), the CRAC (calcium release-activated calcium) channel company, today announced the initiation of CARDEA-Plus, a Phase 2b clinical trial being conducted in the United States and Canada, …

CalciMedica Initiates CARDEA-Plus: A Clinical Trial of Auxora™ in Patients with Critical COVID-19 Pneumonia Read More »

LA JOLLA, Calif., November 2, 2021 – CalciMedica Inc. (“CalciMedica” or the “Company), the CRAC channel company, today announced the appointment of Allan L. Shaw to its Board of Directors. “We welcome Allan to our team and are excited to draw on his impressive background in corporate finance, capital markets, strategic transactions, corporate governance and risk …

CalciMedica Strengthens Board of Directors with Appointment of Finance Veteran Allan L. Shaw Read More »

Reduction in time to recovery through day 60 in patients with moderate and severe respiratory failure (primary endpoint analysis) Statistically significant reduction in time to recovery through day 60 in all patients who received study drug (a pre-specified supplementary analysis of the primary endpoint) Statistically significant 56% relative risk reduction in 30-day all-cause mortality secondary …

CalciMedica Reports Topline Data from the AuxoraTM CARDEA Phase 2 COVID-19 Pneumonia Clinical Trial Read More »

Data provides further evidence of the broad potential for CRAC channel inhibitors to benefit patients across multiple disease areas involving the lungs LA JOLLA, Calif., September 9, 2021 – CalciMedica Inc. (“CalciMedica” or the “Company”), the CRAC channel company, today announced the publication of preclinical data validating calcium release-activated calcium (CRAC) channels, P2Y2 receptors, and P2X receptors …

CalciMedica Announces Publication of Preclinical Data in Journal of Immunology Further Validating Calcium Release-Activated Calcium (CRAC) Channels as Drug Targets for Diseases of the Airways Read More »

Data from Phase 2a Study Demonstrated Patients Treated with Auxora Experienced Reduced Severity of Acute Pancreatitis, Less Persistent Systemic Inflammatory Response Syndrome (SIRS) and More Rapid Restoration of Gut Function with Favorable Safety Profile Patient dosing has begun in Phase 2b study in acute pancreatitis; data expected H2 2022 LA JOLLA, Calif., June 2, 2021 …

CalciMedica Publishes Positive Data from Phase 2a Study of Auxora in Patients with Acute Pancreatitis and Announces First Patients Dosed in Phase 2b Study Read More »

Round led by Quark Venture LP and Global Health Sciences (GHS) Fund Funds to support advancement of anti-inflammatory therapy, AuxoraTM, currently being evaluated in severe and critical COVID-19 pneumonia and acute pancreatitis with SIRS Zafi Avnur, Ph.D., chief scientific officer and partner at Quark Venture, joins Board of Directors LA JOLLA, Calif., March 11, 2021 …

CalciMedica Announces $21 Million Series D Financing Read More »

D-dimer levels have been correlated with disease severity and risk of mortality in patients with COVID-19 Treatment with Auxora improved D-dimer levels in patients with severe COVID-19 pneumonia LA JOLLA, Calif., February 2, 2021 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of …

CalciMedica Presents New Clinical Data Demonstrating Improved D-Dimer Biomarker Levels with Auxora™ in Severe COVID-19 Pneumonia at the 50th Critical Care Congress Read More »

LA JOLLA, Calif., December 17, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (“CRAC”) channels for the treatment of severe acute and chronic inflammatory diseases, today announced that the trial evaluating AuxoraTM in patients with severe COVID-19 pneumonia has received a recommendation to continue, following a pre-scheduled …

CalciMedica Announces IDMC Recommendation to Continue with Trial Evaluating Auxora™ in Patients with Severe COVID-19 Pneumonia Read More »

First report of pathological role for microglial calcium activity in cortical spreading depolarization (CSD), a complication of stroke. CRAC channel inhibitors represent an important future potential therapeutic option for patients with ischemic stroke. LA JOLLA, Calif., November 13, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) …

CalciMedica Announces Publication of Preclinical Data Demonstrating the Pathological Role of Microglial CRAC Channels in Ischemic Stroke Read More »

Mr. Geffken brings more than three decades of financial experience to CalciMedica; involved in 12 IPO filings since 2013 LA JOLLA, Calif., November 5, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, today announced it has …

CalciMedica Appoints Daniel Geffken as Interim Chief Financial Officer Read More »